histidine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hochhaus, A; Lahaye, T; Müller, MC | 1 |
Adamsky, K; Amariglio, N; Ashur-Fabian, O; Cohen, Y; Hardan, I; Nagler, A; Raanani, P; Rechavi, G; Trakhtenbrot, L | 1 |
2 other study(ies) available for histidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Article | Year |
---|---|
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Histidine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Pyrimidines; Selection, Genetic; Tyrosine | 2002 |
Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis.
Topics: Apoptotic Protease-Activating Factor 1; Arginine; Blast Crisis; Gene Expression Regulation, Leukemic; Histidine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Point Mutation; Tumor Suppressor Protein p53 | 2007 |